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ABSTRACT
EFFECT OF TABLET COMPRESSION ON THE DISSOLUTION OF
ASPIRINTABLETS USING A NOVEL OFF-CENTER PADDLE IMPELLER
(OPI) DISSOLUTION TESTING SYSTEM
by
Chuan Sun
In the pharmaceutical industry, dissolution testing is routinely carried out to determine
the dissolution rate of oral solid dosage forms. Among several testing devices, the
USP Dissolution Apparatus 2 is the device most commonly used. However, despite
its widespread use, this apparatus has been shown to produce test failures and to be
very sensitive to a number of small geometry changes.
The objective of this study was to determine whether a novel dissolution
system termed “OPI” for “off-center paddle impeller” was sensitive enough to
determine differences in tablet dissolution profiles caused by different compression
pressure during the tablet manufacturing process. The OPI Dissolution System simply
consists of a modified Apparatus 2 in which the impeller is placed 8mm off center in
the vessel.
In this work, aspirin tablets were manufactured from powder with a manual
tablet press using three different compression pressures. The dissolution profiles of
these tablets were then obtained in both the OPI system and the standard USP
Apparatus 2 system. Tests were conducted by dropping the tablets in the vessels at
the beginning of an experiment, and, in separate experiments, by initially
immobilizing the tablets on the vessel bottom at nine different locations.

This

approach has been used in the past by our group to determine the sensitivity of the
dissolution apparatus to minor changes in the geometry of the dissolution system.
All dissolution profiles were found to be affected by the compression pressure.
Faster dissolution profiles were obtained at lower compression pressures. When
tablets were dropped in the vessel, a comparison of the dissolution profiles obtained in
the standard Apparatus 2 system and in the OPI system showed that similarly
manufactured tablets produced statistically similar dissolution profiles in both
systems, i.e., that the OPI system was just as sensitive as the standard system to
variations in the tablet manufacturing process.

However, when the tablets were

immobilized during the dissolution process, the standard system generated very
different dissolution profiles even for tablets manufactured at the same compression
pressure.

By contrast, the dissolution profiles in the OPI system for tablets

manufactured at different pressure but located at different positions were very similar.
It can be concluded that the OPI system is sensitive enough to detect
differences in intrinsic tablet dissolution rates (such as those caused, as in this case, by
changes in the manufacturing process), while being unaffected by small changes in the
system geometry that instead caused the standard system to fail. Therefore, the OPI
system appears to be a more reliable dissolution testing apparatus than the current
apparatus.
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CHAPTER 1
INTRODUCTION
Dissolution is a process by which the drug substance in a formulation dissolves into
solution. Solid dosage forms such as tablets are the most common used method to
administer drugs. Therefore, dissolution testing is widely used in the pharmaceutical
industry to determine the dissolution rate of solid dosage forms. The dissolution testing is
a critical tool in the process of drug discovery that measuring the stability of the solid
dosage product. Also it‟s an overriding method determining solid dosage drug in-vivo
availability. Thus this Dissolution testing is an essential requirement for the development,
establishment of in vitro dissolution and in vivo performance (IVIVR), registration and
quality control of different dosage forms.
Although the USP lists several different dissolutiontest apparatuses,most dissolution
testsare currently conducted with USP DissolutionTest Apparatuses 1 and 2. The USP
DissolutionTest Apparatus 2 is the most commonly andwidely used apparatus specified
by the USP. The dimensions, characteristics,and operating conditions of USP
DissolutionTest Apparatus 2 are detailed by the USP, 1and all users must conform to these
prescriptionswhen conducting dissolution tests.The USP Dissolution Test Apparatus
2comprises a glass vessel and an agitation system.The glass vessel is a cylindrical glass
tank with asemispherical bottom, and a working volume of900 mL. The agitation system
consists ofa two-blade paddle impeller mounted on a shaftcentrally located in the vessel
and profiled to followthe hemispherical portion of the vessel. In theindustrial practice,
replicate dissolution tests aretypically conducted in parallel using commerciallyavailable
systems containing six or more individualUSP Dissolution Test Apparatus 2 units. These
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systemsallow the agitation system(motor and impellers) to be lifted above the
rackholding the vessels, as shown in this figure, inorder to prepare the system for the
actual test.Each vessel is filled with a prescribed amount of afluid simulating gastric or
intestinal fluids, andmaintained at constant temperature of 37℃byeither a water bath or a
heating jacket.
The USP Dissolution Test Apparatus 2 hasbeen used in the pharmaceutical industry
fordecades, since this test was first officiallyintroduced many years ago.2
Nevertheless,the hydrodynamics of USP Apparatus 2 vessel hasbeen reported to play a
major role in the poor reproducibilityof dissolution testing data and the inconsistencyof
dissolution results.17–19And despite its widespread use in the industry,dissolution testing
remains susceptible to significanterror and test failures. A review of theliterature shows
that there have been numerousreports describing high variability of testresults,3-10 even
when the so called „„calibratortablets‟‟ (i.e., tablets manufactured for the solepurpose of
testing the proper operation of thedissolution test equipment) are used.4,6,9,11,12Failures
linked to dissolution testing resulted inover forty product recalls during the period 2000–
2002,representing 16% of non-manufacturing recalls fororal solid dosage forms.
Irrespective of theunderlying causes (such as incorrect use of theequipment or deviation
of dissolution profile fromthe standard caused by incorrect tablet formulation)failed
dissolution tests can result in productrecalls, costly investigations, potential
productiondelays, which, in turn, can have a significantlynegative financial impact
because standard system isstrongly affectedby even small variations in the geometry of
theapparatus.13-15
In previous experiments16-18, data have shown that OPI System is very reliable.
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Due to the fact that OPI system has faster dissolution rate of the tablet and was
respectively independent to the tablets locations on the bottom of the vessel, we can see
OPI System is more robust and more effective than the Standard System in the
dissolution test. However, whether new system is sensitive enough to detect the slice
difference between tablets is worth to discuss.
The main objective of this study was to verify the sensibility of the OPI system
regarding tablets compression pressure difference. To do so, twodifferent methodologies
were used in this study. Efforts were made to eliminate any other factors that could also
affectthe test results in order to analyze solely tablets compression differences andits
effect on thedissolution profiles in both Standard system and OPI system.
In addition,as shown in previous study on the USP Dissolution Apparatus 2 (Bai
etal., 2007), the exact location of the dissolving tablet introduces significant variations
inthe flow and in the shear stress experienced by the tablet, which, in turn, can affect
thedissolution process and the dissolution profiles. In order to confirm the reliability of
the OPI system, dissolution testswere conducted in USP Dissolution Testing Apparatus
2and in OPI system using tablets with different compression pressure at 9 different
locations at the bottom of the USP Apparatus 2dissolution vessel, i.e., with tablets located
10° or 20° off-center and at different positions. Statistical tools were then used to
evaluate and compare theresults of dissolution profiles in standard system and in OPI
system.
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CHAPTER 2
EXPERIMENTAL APPARATUS, MATERIALS, AND METHOD

2.1 Dissolution Apparatuses
In this work, two dissolution testing apparatus systems were used. A standard USP
Dissolution TestingApparatus 2 (hereafter called the “Standard System”)and a modified
system, which, in this work, isreferred to as “OPI system” for “off-center paddle
impeller”system.
The Standard System consisted of a Distek 5100bathless dissolution apparatus
shown in Figure 2.1(Distek Inc., North Brunswick, New Jersey).Seven dissolution
vessels can be operated at a time. EachUSP Apparatus 2 vessel used as the dissolution
vesselconsisted of an unbaffled, cylindrical, transparentglass tank with a hemispherical
bottom, an internaldiameter, T, of 100.16mm, and an overall capacityof 1L. When the
vessel was filled with 500mLof dissolution media, the corresponding liquid height,H, as
measured from the bottom of the vessel, was78.6mm.
The impeller consisted of a two-blade paddle impeller connected to the
Disteksystem (Distek Inc.) motor with the steel shaft. The exact geometry of each
componentofthe impeller was: shaft diameter, 9.53mm; length of thetop edge of the blade,
74.10mm; length of the bottomedge of the blade, 42.00mm; height of the blade, 19.00mm;
thickness of the blade, 5.00mm. The distancebetween the lower edge of the impeller
bladeand the vessel‟s inside bottom was 25mm. These dimensions were obtained
bymeasuring themwith a caliper. Figure 3a shows the standardUSP Dissolution Testing
Apparatus 2.
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The OPI system was a modification of the standard system(Figure 2.2)in which
the impeller which wasplaced 8mm off center with respect to the vessel
centerline(Figure2.3). To make this change, one of the plastic spring inserts mounted on
the metal plate ofthe Distek dissolution equipment (Distek Inc.), which ensuresthat the
vessel locates at the centerline (Figure2.4), was removed. After removing this plastic
spring insert, the vessel was shifted with respect to the paddle shaft by an exactly 8mm,
thusresulting in an off-centered impeller with respect tothe vessel.The clearance from the
bottom to the paddle end is 25mm, that is, the same as inthe Standard System. Figure 2.3
shows the OPI dissolutiontesting system.

(a)

(b)

Figure 2.1USPdissolution testing System:(a) Distek 5100 bathless dissolution
apparatus,(b) USP dissolution testingapparatus 2: paddle impeller andglass vessel.
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Figure 2.2Standard USP dissolutiontestingapparatus 2.
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Figure 2.3 OPIdissolutiontestingapparatus 2.
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Figure 2.4Modification of the standard system to obtainthe OPI system: (a) vessel in the
standard system, (b) plasticspring inserts exposed after removing the vessel in
thestandard system, (c) system after one of the plastic springinserts has been removed,
and (d) system after the vesselwas repositioned to obtain the OPI system.
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2.2 Experimental Materials
Four types of aspirin tablets were tested in this work, i.e., commercial 360mgwhite, round
shaped uncoated aspirin tablets (Item Code: NDC:59779-249; Active Ingredient: Aspirin
(325 mg); Inactive Ingredient: Starch) with diameter of 11 mm, purchased from CVS
Pharmacy, as well as three other types of tablets obtained by grinding and reconstituting
tablets using different compression tablets.In order to make these tablets, 100 tablets were
well ground to a fine powder using a mortar(Figure 2.6b) and pestle for ten minutes. The
resulting powder was apportioned in 360-mg doses (the mass of each was measured with
an analytical balance). The average tablet mass was measured to be 360±5 mg. Each
dose was then poured in a die and the die was placed in a press (Carver Laboratory Press,
Fred S. Carver Inc.; Model C; Figure 2.5). The powder was manually compressed at the
desired compression pressure. Three compression pressures were used here i.e., 1000
lb/0.12in2, (here referred to as “1000 pound”), 2000 lb/0.12in2 (“2000 pound”), and 3000
lb/0.12in2 (“3000 pound”)(Figure 2.6a), respectively.The compression pressurewas
determined with the pressure gauge connected to the press. All the tablets needed in all
the experiments were manufactured in one single batch to insure the uniformity of the
compressed tablets at each pressure. The resulting tablets consisted of cylindrical disks, 1
cm in diameter and approximately 2-3 mm thick (the actual thickness depended on the
compression pressure).
The dissolution medium for the aspirintablets consisted of a0.05 M acetate buffer
to which glacial acetic acid wasadded to reach a final pH value of 4.5±0.05. This
mediumwas deaerated according to the degassing methoddeveloped by Moore following
the USP GeneralTest Chapter on Dissolution. Accordingly, themedium was placed in a
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carboy tank, which was thenconnected to a vacuum pump. Vacuum was appliedfor 30min,
whereas all other valves in the systemwere closed. This stock solution was used as
needed(typically in 500mL aliquots per experiment).

Figure 2.5 Carverlaboratory press model C.
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(a)

(b)

Figure 2.6(a) From left to right: Commercial tablets, 1000-pound tablets, 2000-pound
tablets, 3000-pound tablets; (b)Mortar used for manufacturing powder.

2.3 Experimental Method
Two testing methods were used here to conduct dissolution tests, as follows.


Testing Method #1: the tablet was dropped in the dissolution medium at the
beginning of the experiment (USP Method);



Testing Method #2: the tablet was fixed in place at one of nine different tablet
positions at the bottom the vessel (i.e., 0°, 10°, 20°) prior to the addition of the
dissolution medium as specified below.

When Testing Method #1 was used, a prescribed volume (500 mL) of the appropriately
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deaerated dissolution medium, previously preheated at 37◦C, was gently poured into the
vessel in order to minimize the introduction of gas. Because of the thermal inertia of the
vessel, the resulting temperature of the liquid was 37◦C. This temperature was maintained
throughout the dissolution experiment by the system‟s temperature controller. Then a
tablet was dropped in the Standard System vessel and another in the OPI System vessel,
agitation was started, and a first set of samples was manually removed as described
below. The agitation speed was 50 rpm for the aspirin dissolution tests in Standard
System, and 36 rpm in the OPI System, as specified in previous work by this group. This
agitation value had been previous identified as the agitation speed at which the OPI
system would generate the same dissolution profile as a standard system stirred at 50 rpm
when a tablet was located at the central position (as better described below).
The time interval between samples was 5 min for the first 30 min, and every 15
min from 30 min to 60 min. Each experiment lasted 60 min, and a total of 8 samples were
taken for each experiment. All experiments were performed in triplicates.
When Testing Method #2 was used, the tablet was glued in place prior to the
addition of the dissolution medium at the beginning of the experiment in order to
determine the sensitivity of the dissolution system to tablet location during a typical
dissolution experiment. Accordingly, a tablet was attached at one of several predefined
locations at the vessel‟s bottom with a very small bead of a commercial acrylic glue prior
to each experiment. Three tablet positions were studied in the Standard System, that is,
the tablet was centered in the vessel, placed 10o off center, or placed 20o off center
(Figure 2.5). This angle originated from the center of the sphere comprising the
hemispherical vessel bottom and was measured starting from the vertical centerline to the
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point of interest, (e.g., the angle would be zero for the central point below the impeller).
As for the OPI system, nine positions at the vessel‟s bottom were selected, as
shown in Figure 2.6. Position O in this figure represents the center of the vessel bottom.
Positions A1–D1 were all 10º off center from the vessel‟s vertical centerline (Figure 2.6).
Positions A1–D1 were all on the same inner circle and were spaced 90ºapart from each
other. Positions A2–D2 were 20º off center from the vessel‟s vertical centerline (Figure
2.6). The vertical centerline through the impeller intersected the vessel‟s bottom between
Position 1 and Position 3, some 8mm away from the vessel‟s bottom.
The vessel with the attached tablet was placed in the Distek apparatus, and then
the appropriate medium volume (500 mL based on USP dissolution test for aspirin) of
deaerated dissolution medium, previously preheated at 37.5◦C, was gently poured into the
vessel in order to minimize the introduction of gas and prevent rapid initial dissolution of
the tablet. Again, because of the thermal inertia of the vessel, the resulting temperature
of the liquid was 37◦C. This temperature was maintained throughout the dissolution
experiment by the system‟s temperature controller. Because of the potential sensitivity of
the process to the initial tablet dissolution caused by liquid addition, extreme care was
taken to ensure that this procedure was consistent and reproducible and that it did not
result in any liquid splashing. The agitation was started immediately after the addition of
the dissolution medium. Sampling was conducted with the same time frequency as
specified above.
Sampling consisted of removing a 10 mL medium aliquot with a 10-mL syringe
connected to a cannula (2 mm internal diameter). The volume of medium removed by
sampling was not replaced, in accordance with the USP procedure (USP, 2012). The
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sampling point was horizontally located midway between the impeller shaft and the
vessel wall, and midway between the top edge of the impeller and the surface of the
dissolution medium, that is, within the sampling zone prescribed by USP. After the
sample withdrawal, about 2 mL of the sample was discarded, the cannula was removed,
and a polyvinylidene fluoride (PVDF) 0.45-m filter was mounted on the syringe. The
remaining sample volume (about 8 mL) was transferred to a vial until analyzed.
Analysis of samples was carried out using 1-cm quartz cells placed in an
ultraviolet (UV)–visible spectrophotometer (Varian Cary 50 Bio, Varian, Inc., Palo Alto,
CA) measuring absorbance at specified wavelengths, that is, 265nm for aspirin.
Beforeputting the quartz cell into the UV spectrometer, the cell was rinsed three times
with the same solution sample.
A calibration curve was obtained bypreparing reference standard solutions of
aspirin tablets with known concentrations to obtain solutions of differentknown
concentrations. In order to obtain a calibration curve, pure aspirin (A2093 Sigma-Aldrich)
was used. The absorbance of these solutionswas obtained in order to generate an
absorbanceversus concentration standard curve. The calibrationcurves were linear
(R2=0.9999 for aspirin) in the concentrationranges of interest here.
Thecalibration

data

and

calibration

curve

for

aspirinusing

the

UV

spectrophotometer to determine the sample absorbance at the wavelength 265nm are
presented in Table 2.2 and Figure 2.6, respectively.

These results showed that the

calibration curve was linear (R2=0.9999) in the concentration range of interest here.
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Table 2.1Operating Conditions for Dissolution Experiments
Medium
Temperature

500 mL, 0.05 M acetate buffer, pH of
4.50 ±0.05
37.5oC

Agitation Speed for Standard System

50 rpm

Agitation Speed for OPI System

36 rpm

Filter
UV Wavelength (UV Spectroscopy)

265 nm

Standard Tablets

CVS Uncoated Aspirin Tablets

Compressed Tablets

CVS Uncoated Aspirin Tablets obtained
at pressure of 1000, 2000, 3000 lb/in2

Time

5-min interval; 60 min total
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20o Circle
10o Circle

B2
B1
A2

A1

O

C1

C2

D1
D2

(a)

(b)
Figure 2.4 Tablet positions in the OPI system and standard system: (a) top view of the
bottom of the dissolution vessel with nine different tablet positions in the OPI system, (b)
the front view of the dissolution vessel with three different tablet positions (0°,10°, 20°)
in the standard system.
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Calibration Curve for Aspirin
concentration, mg/ml

1.2
y = 0.3512x - 0.004
R² = 0.9999

1
0.8
0.6
0.4
0.2
0
0

0.5

1

1.5

2

2.5

3

UV absorbance@265nm

Figure 2.6Calibrationcurve for aspirin
.
Table 2.2 Calibration Data for Aspirin
Absorption 1

Absorption 2

Absorption 3

0

0

0

0

0

0.2885

0.2887

0.2883

0.2885

0.1

0.579

0.576

0.576

0.577

0.2

0.866

0.869

0.86

0.865

0.3

1.151

1.157

1.155

1.154

0.4

1.441

1.443

1.442

1.442

0.5

2.165

2.161

2.163

2.163

0.75

2.844

2.845

2.837

2.842

1
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Average Concentration(mg/mL)

2.4 Data Processing
The dissolution profiles are presented in terms of drug release fraction (mD/mT), that is,
the mass of released drug in the dissolution medium at any time t out of the total mass of
drug initially in the tablet, as a function of time. The absorbance data obtained from the
UV spectrophotometer was first converted to aspirin concentration at given time, (Cj, in
mg/mL), and then transformed into drug mass release fraction (mD/mT) using the
following equations, in order to account for the drug mass removed with each sample:

mD  t1  C1

mT
C*
mD  t j 
mT



for j  1

Cj 
V  V j 1
1

j

1
    Ck
C * 
V  V k 1

(2.1)

for 2  j  n

(2.2)

where j is an index identifying the number of sampling (j=1, 2, … 8), mD(tj) is the mass
of released salicylic acid at time tj, mTis the total mass of salicylic acid initially in the
tablet, Cj is the dissolved aspirin concentration in the jth sampling at time tj, C* is the
concentration of aspirin when the tablet is fully dissolved in 500 mL dissolution medium,
ΔV is each sampling volume (10 mL) and V is the initial volume of dissolution medium
(500 mL). At the beginning of the experiment(t=t1=5 minutes) the first sample was taken
(j=1) resulting in an initial concentration C1, and the 8th sample was taken at t8=60
minutes (j=8).
The dissolution profiles obtained with tablets at each position in the testing
system were compared to those from its paired standard system in order to determine
whether these dissolution curves were statistically similar or not. Two approaches were
used.

The first approach was that recommended by the FDA to quantify the
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similarity/difference of two dissolution profiles. This approach consists of a modelindependent method based on the difference factor (f1) and similarity factor (f2):

n

f1 

R

t

t 1

 Tt

n

R
t 1

 100

(2.3)

t

1 n
f2  50log10 {[1  ( )(Rt  Tt )2 ]0.5  100}
n t 1

(2.4)

where Rtis the reference assay at time t (i.e., the results from the standard system),Τtis the
test assay at the same time (i.e., the paired results from the testing system), and n is the
number of time points. The difference factor(f1) calculates the percent (%) difference
between the two curves at each time point and measures the relative error between two
curves. The higher the f1(which can be in the range of 0 to 100), the higher the average
difference between reference and test curves is (Moore and Flanner, 1996). The similarity
factor (f2) is a logarithmic reciprocal square root transformation of the sum-squared error
of differences between the reference and test profiles over all time points (which can be
in the range -α to 100). The higher the f2, the lower the average difference between
reference and test curves is (Costa and Lobo, 2001). Public standards have been set by
FDA for f1and f2 factors. Accordingly, statistical similarity between the two curves being
compared requires that 0<f1<15 or 50<f2<100(FDA, 1997).
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CHAPTER 3
RESULTS
The drug release profile of aspirin tablets compressed at different pressures used regular
dissolution method in the standard USP Dissolution Testing Apparatus 2. Then the drug
release profile of aspirin tablets with different pressures used regular dissolution method
in the OPI system. The dissolution profile of aspirin tablet with different pressures at
three different tablet locations (0°, 10°and 20°) in the Standard USP Dissolution Testing
Apparatus 2 (Standard System) were obtained third as per USP method. The forth is the
drug release profile of aspirin tablet with different pressures at nine different tablets
locations was obtained for the Modified System as per the method described in the
previous chapter. The results were interpreted by potting mD/mT (%)(drug release) against
time (min) and by calculating similarity factor (f1) and difference factor (f2).

3.1Results for Dissolution Tests in the Standard USP Dissolution Testing Apparatus
by Dropping Tablets into Medium Using Testing Method #1

In the Standard USP Dissolution System, the dissolution profiles for aspirin tablet were
obtained by dropping into the dissolution vessel under an agitation speed of 50 rpm. The
results are reported here in terms of drug release ratiomD/mT(%). Figure 3.1 presents these
results.
Based on the USP specifications for the Aspirin tablets used in this work, each
individual run should produce a dissolved amount of aspirin no less than 80% (Q) of the
labeled amount of C9H8O4 contained in the tablet (360 mg) when sampling at 30
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minutes. This is the case here for the centrally located tablet, since the experimentally
obtained fractions at 30 minutes were found to be 87.49%, implying that the equipment
was suited to conduct dissolution testing with aspirin tablets.
A noticeable difference of dissolution profiles between different tablets
compression pressures was found through the figure 3.2. Three curves started at the same
mass at the beginning, butthey diverged with time depending on the tablet with different
compression pressure.The dissolution curve for the commercial tablet began atmD/mT = 0,
and then increased fast, reaching mD/mT = 68% at10th min. After 10 min, a lowerrelease
rate of Commercial tablets was observed.from45min, the release rate of commercial
tablets almost kept constant. For tablets with 1000-pound compression pressure, its
dissolution profile was extremely similar to the commercial tablets, figure 3.1 showed the
tendency of the similarity. According to Table 3.1, f1and f2 values of the 1000-pound
tablets reached 2.97 and 75.90 respectively, indicating the similarity between commercial
tablets and 1000-pound tablets. For tablets with compression pressure of 2000 pound and
3000 pound, a significant difference was found in the figure 3.1, especially for the 3000pound tablets. At t =5min, the dissolution curves were foundto be much lower than the
dissolution curve of commercial tablets, only reaching mD/mT = 50%. After 5 min, the
dissolutionrates increased slightlyrespect to time. At t=60 min, mD/mT value of 3000
pound tablets was 10% lower than the mD/mT value of commercial tablets. Respectively,
the f1and f2 values of the 2000-pound tablets were 5.65, 65.3, and f1and f2 values of the
3000-pound tablets were over 10 and lower than 56.Based on the f1and f2 values listed
above (table. 3.1), the difference between the dissolution profiles for aspirin tablets with
different compression pressure in the standard system could be easily recognized.
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Although f1and f2 values fortablets with pressure of 2000 pound and 3000 pound were
within FDA range, the difference still existed, which verified the existence of the
difference produced by different tablets compression pressure.
In addition, f1 and f2 values reported in Table 3.1 implied that tablets with the
pressure of 1000 pound, 2000 poundand 3000 pound would have different dissolution
profiles despite a certain degree of similarity was shown. These results confirm that the
dissolution profiles of aspirin tablets depend on the compression pressure.
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Figure 3.1Dissolution profiles of aspirin tablets with different pressures in standard
system by dropping tablets into medium using testing method #1.

Table 3.1f1 and f2 Value of Tablets with Different Pressure in Standard System by
Dropping Tablets into Medium Using Testing Method #1.
Tablet Location
Standard Tablets
Tablets with 1000 pound pressure
Tablets with 2000 pound pressure
Tablets with 3000 pound pressure

f1 (Similarity factor)

f2 (Difference factor)

2.97
5.66

75.70
65.29
55.07

10.39

30

3.2Results for Dissolution Testsin the OPI Systemby Dropping Tablets into Medium
Using Testing Method #1

The dissolution difference between pressures were tested in standard system by USP
method, the similar dissolution profiles in the standard system were found in OPI system,
which indicated the sensitivity of the OPI system can be verified.
f1 and f2 methods were used to identify the similarity/difference between aspirin
tablets with different pressures in OPI system. Meanwhile, f1 and f2 methods were used to
analyze the dissolution data of tablets with same pressure in two systemsin order to
compare the tablets dissolution profiles with same pressure under standard system and
OPI system.
A difference between different pressures was also foundin OPI system through
the figure 3.2.1. The corresponding f1 and f2 values quantifying the similarity/difference
of the dissolution profiles with different pressures are presented in the Table 3.2.1. In this
case, f1 was foundto be in the range 2.3–10.0, stating a relatively small differencebetween
the release profiles at different compression pressures and the reference release
profile(standard tablets); f2values in this part were found to be in therange 55.2–
78.8,indicating that the release profiles were statisticallysimilar to the reference release
profile, however as previous experiment, f1 value of tablets with 3000 pound pressure
was 10.41, which was much higher than the f1 of tablets with 1000 pound, that is 2.3, and
2000 pound, that is 4.9. The comparison between standard system and OPI system in
each particular tablet pressure were shown in Figure 3.2.2-3.2.5. According to f1 and f2
values in table 3.2.2-3.2.5, one fact can be seen that f1 and f2 values between experiments
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operated under standard system and experiments operated under OPI system were
corresponding, indicating that like standard system, OPI system was sensitive enough to
detect differences of the tablets.
The comparison between tablets with each compression pressure was conducted
in this section. f1 and f2 values of tablets with every compression pressure between OPI
and standard system were shown Table 3.2.2-3.2.5. Through the Figure 3.2.2-3.2.5, and
the Table 3.2.2-3.2.5, curves of tablets dissolution profiles were highly corresponding.
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Figure 3.2.1Dissolution profiles of aspirin tablets with different pressures in OPI system
by dropping tablets into medium using testing method #1.

Table 3.2.1f1 and f2 Value of Tablets with Different Pressure by Dropping Tablets into
Medium Using Testing Method #1.
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Standard Tablets
Tablets with 1000 pound pressure
2.29
78.78
Tablets with 2000 pound pressure
4.96
69.05
Tablets with 3000 pound pressure
10.02
55.28

33

Dropped Commercial Tablets in Standard System
and OPI System
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Figure 3.2.2 Comparison of dissolution profiles of aspirin commercial tablets in standard
system and OPI system by dropping tablets into medium using testing method #1.

Table 3.2.2f1 and f2 Values of Aspirin Commercial Tablets In OPI System by Dropping
Tablets into Medium Using Testing Method #1.
Tablet Location
f1 (Similarity
f2 (Difference
factor)
factor)
Dropped commercial tablets in standard system
Dropped commercial tablets in OPI system
3.46
75.48
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Figure 3.2.3Comparison of dissolution profiles of aspirin 1000-pound tablets in standard
system and OPI system by dropping tablets into medium using testing method #1.

Table 3.2.3f1 and f2 Values of Aspirin 1000-Pound Tablets In OPI System by Dropping
Tablets into Medium Using Testing Method #1.
Tablet Location
f1 (Similarity
f2 (Difference
factor)
factor)
Dropped 1000-pound tablets in standard system
Dropped 1000-pound tablets in OPI system
2.44
80.12
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Dropped 2000-Pound Tablets in Standard
System and OPI System
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Figure 3.2.4Comparison of dissolution profiles of aspirin 2000-pound tablets in standard
system and OPI system by dropping tablets into medium using testing method #1.

Table 3.2.4f1 and f2 Values of Aspirin 2000-Pound Tablets In OPI System by Dropping
Tablets into Medium Using Testing Method #1.
Tablet Location
f1 (Similarity
f2 (Difference
factor)
factor)
Dropped 2000-pound tablets in standard system
Dropped 2000-pound tablets in OPI system
4.06
72.17
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Dropped 3000-Pound Tablets in Standard
System and OPI System

100
90
80

mD/mT (%)

70
60
50
40
Dropped 3000-Pound Tablets in
Standard System

30
20

Dropped 3000-Pound Tablets in
OPI System

10
0
0

10

20

30

40

50

60

70

t (min)
Figure 3.2.5Comparison of dissolution profiles of aspirin 3000-pound tablets in standard
system and OPI system by dropping tablets into medium using testing method #1.

Table 3.2.5f1 and f2 Values of Aspirin 3000-Pound Tablets In OPI System by Dropping
Tablets into Medium Using Testing Method #1.
Tablet Location
f1 (Similarity
f2 (Difference
factor)
factor)
Dropped 3000-pound tablets in standard system
Dropped 3000-pound tablets in OPI system
3.84
75.33

3.3Results for Tablets at Three Positions in the Standard USP Dissolution
TestingApparatus 2 Using Testing Method #2
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There are various factors that affect the drug release profile in USP Dissolution
Apparatus 2. A number of studies related to the location of tablet and impeller, presence
of baffles, geometric effects of the vessel, and even vibration effects ondrug dissolution
rate have been carried on.The position may vary from time to time when the tablet
reaches the vessel bottom. Therefore, tablet location has a major effect, and that
statistically significant differences exist in the dissolution profiles between centrally
located tablets and tablets positioned off-centered.
In the Standard USP Dissolution System, the dissolution profiles for aspirin tablet
was obtained at three different tablet locations (0°, 10°, 20°) on the bottom of the
dissolution vessel under an agitation speed of 50 rpm. Figure 3.4.1-3.4.4 presentthese
results.
There was a significant difference between all three dissolution profiles at three
different tablet positions.As the data showed in figure 3.3.1, the fact was foundthe greater
the distance from the central location,the higher the dissolution rate. In the figure 3.3.1,
the dissolution curve of tablets in central position was similar to the dissolution curve for
tablets dropped into the medium using method #1. With the increasing of the deviation of
the distance to the centerline, the dissolution rate of the tablets increased obviously. The
corresponding f1 and f2 values quantifying the similarity/difference of the dissolution
profiles with respect to that for the centrally located tablet are presented in the Table
3.4.1. Even thoughf1 and f2 are in the required range to insure statistical similarity, f1 of
tablets at 20°locations is much higher than the value of tablets at 10°locations, which
imply that the dissolution profile difference exists. These results confirm that the
dissolution profiles of the aspirin tablets depend strongly on the tablet location in the

38

dissolution vessel for the Standard System.These results are in agreement with previously
reported work from this and other research groups.
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Figure 3.3.1Dissolution profiles of commercial tablets at 3 positions in standard system

Table 3.3.1f1 and f2 Value of Commercial Tablets at 3 Positions in Standard System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Tablets using official method
Tablets at center
3.06
80.20
Tablets at 10°off-center
8.63
59.99
Tablets at20°off-center
10.67
55.64
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Figure 3.3.2 Dissolution profiles of 1000-pound tablets at 3 positions in standard system

Table 3.3.2f1 and f2 Value of 1000-Pound Tablets at 3 positions in Standard System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Tablets using official method
Tablets at center
1.35
91.68
Tablets at 10°off-center
3.46
77.57
Tablets at20°off-center
7.97
60.59
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Figure 3.3.3 Dissolution profiles of 2000-pound tablets at 3 positions in standard system

Table 3.3.3f1 and f2 Value of 2000-Pound Tablets at 3 positions in Standard System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Tablets using official method
Tablets at center
0.22
99.25
Tablets at 10°off-center
3.80
76.44
Tablets at20°off-center
8.18
61.27
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3000-Pound Tablets in Standard System
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Figure 3.3.4 Dissolution profiles of 3000-pound tablets at 3 positions in standard system

Table 3.3.4f1 and f2 Value of 3000-Pound Tablets at 3 positions in Standard System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Tablets using official method
Tablets at center
0.24
99.55
Tablets at 10°off-center
5.69
70.50
Tablets at20°off-center
10.22
58.41

3.4Results for the Tablets at Nine Positions in OPI System Using Testing Method #2

In all dissolution tests with the modified system, the aspirin tablets remained at their
initial location for the entire duration of the experiment. Since the tablets did not
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disintegrate, the dissolution process was driven by erosion. In order to compare the
profiles of off-center tablets with centrally located tablets, the similarity values f1 and
difference values f2 were used. Table 3.4.1-3.4.4 shows the f1 and f2 valuesof off-center
dissolution profiles comparing with the dissolution profile of the centrally located tablets.
In all cases, when compared to the dissolution profiles in OPI system by dropping
in this case,f1 values were in the range 2-4, much lower than the upper limit required by
FDA for similarity (15), and f2 values were in the range and more than 75, within the
FDA range 50-100. Thus, all values were within the acceptance level. Indicating offcenter dissolution profiles were statistically similar to the baseline profile obtained from
centrally located tablets in the modified USP Dissolution Apparatus 2 and the OPI system
can avoid the interferes from tablets initial location.. As shown in Figure below, one can
easily see the OPI system is robust enough.
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Figure 3.4.1 Dissolution profiles of commercial tablets at 9 positions in OPI system

Table 3.4.1f1 and f2 Value of Commercial Tabletsat 9 Positions in OPI System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Dropped tablets
Tablets at position O
2.64
81.03
Tablets atposition A1
3.36
76.63
Tablets atposition B1
3.41
76.04
Tablets atposition C1
3.56
74.71
Tablets atposition D1
3.16
76.85
Tablets atposition A2
3.23
77.21
Tablets atposition B2
2.95
78.81
Tablets atposition C2
2.76
80.57
Tablets atposition D2
2.48
81.87
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Figure 3.4.2Dissolution profiles of 1000-pound tablets at 9 positions in OPI system

Table 3.4.2f1 and f2 Value of 1000-Pound Tablets at 9 Positionsin OPI System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Dropped tablets
Tablets at position O
2.59
80.24
Tablets atposition A1
3.07
77.72
Tablets atposition B1
1.83
86.84
Tablets atposition C1
2.50
82.02
Tablets atposition D1
2.95
79.52
Tablets atposition A2
2.29
83.59
Tablets atposition B2
2.20
84.24
Tablets atposition C2
2.51
82.69
Tablets atposition D2
2.49
82.49
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2000-Pound Tablets in OPI System
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Figure 3.4.3Dissolution profiles of 2000-pound tablets at 9 positions in OPI system

Table 3.4.3f1 and f2 Value of 2000-Pound Tablets at 9 Positionsin OPI System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Dropped tablets
Tablets at position O
Tablets atposition A1
Tablets atposition B1
Tablets atposition C1
Tablets atposition D1
Tablets atposition A2
Tablets atposition B2
Tablets atposition C2
Tablets atposition D2

2.94
2.87
3.55
2.42
3.13
1.97
3.73
3.78
2.62
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80.65
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3000-Pound Tablets in OPI System
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Figure 3.4.4Dissolution profiles of 3000-pound tablets at 9 positions in OPI system

Table 3.4.4f1 and f2 Value of 3000-Pound Tablets at 9 Positionsin OPI System
Tablet Location
f1 (Similarity factor) f2 (Difference factor)
Dropped tablets
Tablets at position O
Tablets atposition A1
Tablets atposition B1
Tablets atposition C1
Tablets atposition D1
Tablets atposition A2
Tablets atposition B2
Tablets atposition C2
Tablets atposition D2

3.03
3.51
3.27
2.61
3.58
3.55
3.31
3.03
3.91
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79.43
77.36
78.29
81.83
77.76
76.71
78.85
79.72
75.65

CHAPTER 4
DISCUSSION

In previous work16-18, OPI system was found more robust than the standard USP method.
In order to determine OPI is also sensitive enough to detect the difference as USP
standard method does under the change of experimental condition, further experiments
were conducted. Due to the fact that tablets with different pressures might have different
dissolution profile, the pressure difference was selected as the variable in the test.
According to USP specification, USP method in Apparatus 2 was used firstly to see
whether the difference of dissolution profiles exists under different aspirin tablets with
different pressures. Results showed that tablets with different pressures had different
dissolution curves. If the similar results concluded by OPI system, the sensibility of the
OPI system can be verified.
A difference between different pressures was found in both systems through the
figure. f1values was foundto be in the range 2.0–11.0 and f2values in this part were found
to be in therange 55.0–79.0 in both systems. f1 values of tablets with 1000 pound, 2000
pound and 3000 pound in standard system were 2.9, 5.7 10.4 respectively, meanwhile, in
Table 3.2.1,f1values of tablets dissolution profiles in OPI system using testing method#1
were 2.3, 4.9 and 10.0; on the other hand, f2values of both systems were corresponding as
well. f1and f2values of tablets with specific pressure were shown in the Table 3.2.2-3.2.5,
indicating in OPI system, dissolution profiles of tablets with different pressures were
extremely similar, that is, just like standard system; OPI system was sensitive enough to
detect differences of the tablets.
In the following experiments, significant difference in dissolution performance
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can be seen between off-center and centered tablets in the Standard System. A small
tablet off-center displacement of only 10°is already capable of producing significantly
and statistically different dissolution results, with f1 value of 8.63, more than f1value of
central tablets, 3.05 when compared to the curves of dropped tablets as reference curve.
When the displacement reaches 20°off-center, f1 value turns to be 10.67, indicating that
greater deviation of the tablet location from the centerline can produce larger deviation in
dissolution profiles.
Distance effect did not exist in the OPISystem. Greater deviations of the tablet
location from the centerline hadsimilar results as the central location tablets in the
dissolution profiles, which is different to the Standard System. As shown in Table 3.4.13.4.4. That is,all the deviations are within the acceptable range guided by FDA. Thus,
tablet locations in the bottom of the vessel are not that important in the OPI System. In
typical dissolution tests, the OPI testing apparatus is robust enough to produce similar
dissolution profiles even the tablet is freely dropped into the testing vessel at 50 rpm
agitation speed.
According to previous work, the reason for this improvement resides in the
deliberateremoval of the symmetry, obtained by positioningthe impeller off center with
respect to thevessel, as proposed here for the OPI system. In theStandard System, the
symmetric position of the impellergenerates a poorly mixed region just belowthe
impeller,precisely where the tablet is usuallylocated
In sum, the results of this work confirm that dissolution of aspirin tablets
issignificantly affected by the exact location of the dissolvingtablet, as also described in
previous work.However, and more importantly, this work additionallyshows that OPI
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system can obviate to this problem and resultin amuchmore robust dissolution testing
system. On the other hand, a good sensibility to the difference of the tablets showed in
the work, indicating the OPI system is sensitive enough to analyze the tablets while it has
a strong independence to the effect factors such as the deviation of the tablet location
from the centerline.In addition, the OPI system is expectedto require very low capital
investment for its commercialimplementation and minimal retraining ofpersonnel, while
providing a much more robust testthat is insensitive to tablet location and, most likely,to
other small geometric imperfections in the equipmentand to small operator-dependent
variations inthe test procedure.
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CHAPTER 5
CONCLUSIONS

The following conclusions can be drawn from this work:
1. Dissolution tests conducted using aspirin tablets with different compression pressures
in the standard USPDissolution Testing Apparatus2 resulted in dissolution curves that
werenot statistically similar(using both f1 and f2) respectiveof the tablets pressures,
indicating that tablets pressure in this particular case is one of the variables, which
causes the different dissolution profiles and can be detected in the standard
USPDissolution Testing Apparatus2.

2. By contrast, similar tests conducted usingthe standard USPDissolution Testing
Apparatus2 resulted in dissolution curves that werealso statistically similar just as the
former case. Additionally, f1 and f2 of each curve was corresponding, stating that the
OPI system was sensitive enough to detect the slice difference between tablets as
standard USPDissolution Testing Apparatus2 did.

3. In this work the dissolution performance of aspirin tablets with different pressures in
the Standard Dissolution System where the impeller is placed centrally and
symmetrically with respect to the unbaffled hemispherical-bottom vessel of the USP
Dissolution Testing Apparatus 2 is strongly dependent on tablet position, as
previously reported by this and other research groups. Thus, this apparatus is prone
to highly variable results which may not be associated with the tablets undergoing
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testing but with hydrodynamic characteristics of the apparatus itself and the location
of the tablet on the vessel bottom.

4. OPI system of the USP Dissolution Testing Apparatus 2 in which the impeller was
placed off-center by 8 mm was proposed, and a prototype was assembled, and tested
in this work. This OPI system generated dissolution profiles for aspirin tablets that
were nearly completely insensitive to tablet location. And when compared to the
results in OPI system by dropping the tablets, similarity of the results can be easily
seen, which states OPI system is not only sensitive enough to detect the slice
experimental condition differences, but also much more robust than the Standard
Dissolution System.
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Appendix A
DERVIATION OF EQUATION 2.1

In this appendix, Equation 2.1 in Section 2.4 was derived based on the mass balance inthe
dissolution system.

Thedrug release ratio needed to be determined:

i.e., the amount of drug in solution at any time t out of the total initial amount ofdrug in
the tablet.
The initial volume of solution (medium) is V, and each sample has a volumeequal to V.
Also, the mass of drug initially in the tablet is:
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In general, at any time t just after taking a sample, the mass balance for the drugremoved
from the tablet (and transferred to the solution) gives:

In our system, the tablet was dropped in the medium at t=to, the agitation wasimmediately
started, and a sample was taken (at t=t1=5 min).:

For t=t1 (corresponding to a sample concentration C=C1) the mass balance gives:

For t=t2 (corresponding to a sample concentration C=C2):

For t=ti(corresponding to a sample concentration C=Ci):
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For t=tn(corresponding to a sample concentration C=Cn):

Hence, for t=tn(corresponding to a sample concentration C=Cn):

and finally:

Remark: in this study first sample was taken at t=t1=5 min. Thismeans that the 9h sample
corresponds to n=9, i.e.,n= 1, 2, 3, 4, 5, 6, 7 and 8(9 samples taken every 5 minutes,
starting at time t=t1=5min, and ending at time t8=60 minutes).
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Appendix B
DISSOLUTION OF TABLETS WITH DIFFERENT COMPRESSION
PRESSURES AT EACH POSITION OF NINE POSITIONS IN OPI SYSTEM
In this appendix, dissolution profiles of aspirin tablets in are plotted as concentration ratio
mD/mT (%) vs. time in Figure B.1 to B.9.
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Figure B.1Dissolution profiles of tablets with different pressures at position Oin OPI
system.
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Figure B.2 Dissolution profiles of tablets with different pressures at position A1 in OPI
system.
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Figure B.3 Dissolution profiles of tablets with different pressures at position B1 in OPI
system.
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Tablets in Position C1
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Figure B.4 Dissolution profiles of tablets with different pressures at position C1 in OPI
system.
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Figure B.5 Dissolution profiles of tablets with different pressures at position D1 in OPI
system.
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Figure B.6 Dissolution profiles of tablets with different pressures at position A2 in OPI
system.
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Figure B.7 Dissolution profiles of tablets with different pressures at position B2 in OPI
system.
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Figure B.8 Dissolution profiles of tablets with different pressures at position C2 in OPI
system.
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Figure B.9 Dissolution profiles of tablets with different pressures at position D2 in OPI
system.
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